How to Commercialize a Medical Device

Mike Hull • September 1, 2026

Medical-device commercialization is an exercise in integration. Engineering, clinical evidence, regulatory strategy, human factors, quality systems, manufacturing, reimbursement, and customer workflow all interact. Decisions made in one area can create cost or delay in another.

1. Lock the Clinical Problem and User

A device should be designed around a specific user, use environment, and clinical problem. 'Surgeons' or 'hospitals' is not enough. Identify the procedure, workflow, setting, purchasing stakeholder, and measurable improvement.

2. Identify Classification and Regulatory Pathway

FDA generally reviews moderate-risk devices through 510(k) when an appropriate predicate exists; novel low- to moderate-risk devices may use De Novo; high-risk devices generally require PMA. Some low-risk devices are exempt from premarket review. The pathway influences evidence, design controls, timeline, and financing needs.

3. Design for Evidence, Usability, and Manufacturability

Prototype work should not optimize technical performance in isolation. Incorporate design inputs, risk management, human factors, verification and validation, sterilization or biocompatibility needs where applicable, and a path to scalable manufacturing.

4. Use FDA Interaction Strategically

When the pathway, testing plan, or clinical strategy contains meaningful uncertainty, the Q-Submission/Pre-Submission process can be used to seek FDA feedback before committing to expensive studies.

5. Validate the Buying Process

The person who uses the device may not control the purchase. Map the economic buyer, clinical champion, value-analysis committee, hospital administration, supply chain, distributor, or other decision-makers.

6. Plan Reimbursement and Economics

Determine whether the device is paid separately, bundled into a procedure, covered through an existing code, or dependent on a new payment pathway. Even when reimbursement is indirect, the economic value proposition must be clear.

7. Finance to Regulatory and Commercial Milestones

Build the budget around prototypes, verification, regulatory interaction, submission, clinical evidence, manufacturing transfer, and launch—not just monthly burn. Each financing round should reach a milestone that meaningfully reduces risk.


BYB Takeaway

A medical device is not commercially ready because the prototype works. It is ready when the product, evidence, regulatory pathway, manufacturing process, workflow, buyer, and economics fit together.

Design the commercialization system at the same time you design the device.

Source notes

FDA, Medical Device Safety and the 510(k) Clearance Process: https://www.fda.gov/medical-devices/510k-clearances/medical-device-safety-and-510k-clearance-process

By Mike Hull September 14, 2026
Commercialization requires a second layer of work: translating the discovery into a defined use case, protectable asset, development plan, evidence package, and funding strategy that a customer, licensee, investor, or strategic partner can act on.
By Mike Hull September 13, 2026
It is the operating logic that explains how a scientific asset can move from its current state to a product that can be funded, licensed, approved, adopted, reimbursed, partnered, or sold.
By Mike Hull September 12, 2026
There is no universal amount of validation required before a biotech company raises capital. Investors fund risk, so a company does not need every question answered.
By Mike Hull September 11, 2026
For university inventors, one of the most important commercialization decisions is whether to license the technology directly to an established company or form a startup to develop it further.
By Mike Hull September 10, 2026
The Bootstrap Score™ is a practical framework for asking a more useful question: how much of the commercial risk has been reduced around the science?
By Mike Hull September 9, 2026
A paper can establish an important scientific finding, while a buyer, investor, regulator, licensee, or strategic partner may still see substantial unanswered risk.
By Mike Hull September 8, 2026
There is another risk that receives less attention—the Valley of Dilution™. It occurs when a company raises expensive equity before key uncertainties have been reduced.
By Mike Hull September 7, 2026
The Bootstrap Flywheel™ is a different model: use each small de-risking step to make the next step easier, cheaper, and more credible.
By Mike Hull September 6, 2026
The most important financing question for an early biotech company is often not how much money to raise. It is what type of money should fund the next milestone.
By Mike Hull September 5, 2026
Venture capital is not inherently too early or too expensive. It becomes expensive when founders use it to answer questions that could have been answered first with smaller or less dilutive resources.